NASDAQ:RLAY Relay Therapeutics (RLAY) Stock Price, News & Analysis $18.45 +1.36 (+7.96%) Closing price 10/20/2026 04:00 PM EasternExtended Trading$18.45 0.00 (0.00%) As of 10/20/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Relay Therapeutics Stock (NASDAQ:RLAY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Relay Therapeutics alerts:Sign Up Key Stats Today's Range$17.01▼$18.6950-Day Range$16.28▼$20.7452-Week Range$5.95▼$21.27Volume1.98 million shsAverage Volume2.91 million shsMarket Capitalization$4.04 billionP/E RatioN/ADividend YieldN/APrice Target$25.92Consensus RatingModerate Buy Company Overview Relay Therapeutics, Inc. is a biotechnology company focused on discovering and developing medicines for cancer and other serious diseases. The company uses its Dynamo platform, which combines structural biology, computational modeling, machine learning and experimental science to study how proteins move and interact. Relay aims to use this approach to identify precisely targeted therapies, including medicines designed to bind to previously difficult-to-drug sites. The company’s pipeline has primarily focused on oncology, including investigational small-molecule therapies directed at cancer-driving proteins and signaling pathways. Its programs have included treatments targeting PI3K alpha, FGFR2 and other molecular targets, although candidates and development priorities may change as clinical research progresses. Relay’s products remain investigational and are subject to clinical testing and regulatory review. Relay Therapeutics was founded in 2016 and is headquartered in Cambridge, Massachusetts. The company has advanced its programs through internal research as well as collaborations and partnerships with other biopharmaceutical organizations. Sanjiv Patel serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Relay Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreRLAY MarketRank™: 2.415932746195 of 5 starsRelay Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 646th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingRelay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 2 strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialRelay Therapeutics has a consensus price target of $25.92, representing about 40.5% upside from its current price of $18.45.Amount of Analyst CoverageRelay Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Relay Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Relay Therapeutics are expected to decrease in the coming year, from ($1.61) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -11.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -11.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 5.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Relay Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.46% of the float of Relay Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 12.59, which indicates bearish sentiment.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 5.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.22 News SentimentRelay Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Relay Therapeutics this week, compared to 4 articles on an average week.Search Interest3 people have searched for RLAY on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows8 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $119,185,022.00 in company stock.Percentage Held by Insiders5.04% of the stock of Relay Therapeutics is held by insiders.Percentage Held by Institutions96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relay Therapeutics' insider trading history. Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RLAY Stock News HeadlinesRelay: The Recent Market Excitement Ignores The Reality Of Clinical Risks And Patent CliffsOctober 17, 2026 | seekingalpha.comRelay Therapeutics (NASDAQ:RLAY) Stock: Insider Thomas Catinazzo Sells 17,717 SharesOctober 9, 2026 | insidertrades.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Relay Therapeutics Insider Sold Shares Worth $329,322, According to a Recent SEC FilingOctober 8, 2026 | marketscreener.comMRelay Therapeutics (RLAY) Stock Looks Fully Priced On Book ValueOctober 8, 2026 | uk.finance.yahoo.comIs Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?October 8, 2026 | finance.yahoo.comRelay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comRelay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks TranscriptSeptember 10, 2026 | seekingalpha.comSee More Headlines RLAY Stock Analysis - Frequently Asked Questions How have RLAY shares performed this year? Relay Therapeutics' stock was trading at $8.46 at the beginning of 2026. Since then, RLAY stock has increased by 118.1% and is now trading at $18.45. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) released its earnings results on Thursday, August, 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.02. The firm earned $0.35 million during the quarter, compared to analyst estimates of $0.96 million. When did Relay Therapeutics IPO? Relay Therapeutics (RLAY) raised $370 million in an IPO on Thursday, July 16th 2020. The company issued 20,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Relay Therapeutics' major shareholders? Relay Therapeutics' top institutional investors include Congress Asset Management Co. (0.36%) and GAMMA Investing LLC. Insiders that own company stock include Pauling (Cayman) Ltd Svf, Sanjiv Patel, Donald A Bergstrom, Brian Adams, Peter Rahmer and Thomas Catinazzo. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM) and Micron Technology (MU). Company Calendar Last Earnings8/06/2026Today10/20/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RLAY's financial health is in the Green zone, according to TradeSmith. RLAY has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RLAY CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees192Year Founded2016Price Target and Rating Average Price Target for Relay Therapeutics$25.92 High Price Target$31.00 Low Price Target$18.00 Potential Upside/Downside+40.5%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$276.48 million Net MarginsN/A Pretax Margin-2,763.64% Return on Equity-42.27% Return on Assets-38.67% Debt Debt-to-Equity RatioN/A Current Ratio18.27 Quick Ratio18.27 Sales & Book Value Annual Sales$15.35 million Price / Sales263.40 Cash FlowN/A Price / Cash FlowN/A Book Value$3.27 per share Price / Book5.64Miscellaneous Outstanding Shares219,140,000Free Float208,097,000Market Cap$4.04 billion OptionableOptionable Beta1.72 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:RLAY) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
